| Chan DC |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=1.985 ------>paper_class3=2 ------>paper_class2=1 ------>vol=14 ------>confirm_bywho=None ------>insert_bywho=jhchen ------>Jurnal_Rank=4.3 ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=93 ------>medlineContent= ------>unit=000 ------>insert_date=20090306 ------>iam=7 ------>update_date=None ------>author=??? ------>change_event=1 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Annals Surg Oncol ------>paper_name=Evaluation of serum amyloid A as a biomarker for gastric cancer. ------>confirm_date=None ------>tch_id=097132 ------>pmid=17063306 ------>page1=84 ------>fullAbstract=BACKGROUND: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. METHODS: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. RESULTS: The mean SAA concentration was higher in gastric cancer patients (88.54 +/- 50.44 mg/l) than in healthy subjects (3.36 +/- 2.29 mg/l) and gastric ulcer patients (10.48 +/- 8.97 mg/l) (P < .05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren~s histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P < .0001) and lymph node status (P < .05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P < .05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. CONCLUSIONS: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. ------>tmu_sno=None ------>sno=21196 ------>authors2=Chen CJ ------>authors3=Chu HC ------>authors4=Chang WK ------>authors5=Yu JC ------>authors6=Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH. ------>authors6_c= ------>authors=Chan DC ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Evaluation of serum amyloid A as a biomarker for gastric cancer. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=1 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2007 ------>submit_flag=None ------>publish_month=1 |